Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on cerebrovascular atherosclerosis and white matter abnormalities as determined by MRA and MRI: A placebo-controlled, randomized trial

European Journal of Clinical Investigation

Volumn 34, Issue 4, 2004, Pages 256-261

  Vermeulen, E G J ^a,c,d   Stehouwer, C D A ^a,c   Valk, J ^a   Van Der Knaap, M ^a,c   Van Den Berg, M ^a,c   Twisk, J W R ^b   Prevoo, W ^a,c   Rauwerda, J A ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Department of Vascular Surgery ^*  (Netherlands)

^d GELRE HOSPITALS   (Netherlands)

Author keywords

Cerebral atherosclerosis; Folic acid; Homocysteine; MRI; Vitamin B6

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; METHIONINE; PLACEBO; PYRIDOXINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BRAIN ATROPHY; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR DISEASE; CLAUSTROPHOBIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE MARKER; DRUG EFFECT; DRUG SCREENING; FEMALE; FOLIC ACID BLOOD LEVEL; FOLLOW UP; HEMOCONCENTRATION; HUMAN; HYPERHOMOCYSTEINEMIA; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIBLING; VERTEBRAL ARTERY; VITAMIN BLOOD LEVEL; WHITE MATTER;

ADULT; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CEREBROVASCULAR CIRCULATION; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLIC ACID; HEMATINICS; HOMOCYSTEINE; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; VITAMIN B 6;

EID: 2142757272     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01332.x     Document Type: Article

References (29)

1. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
2. Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst (e) ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998;29:2478-83.
3. Evers S, Koch HG, Grotemeyer KH, Lange B, Deufel T, Ringelstein EB et al. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol 1997;54:1276-82.
4. Ducloux D, Chalopin JM. Homocysteine in cerebral macroangiopathy and microangiopathy. Lancet 1999;354:1029-30.
5. Fassbender K, Mielke O, Bertsch T, Nafe B, Froschen S, Hennerici M et al. Homocysteine in cerebral macroangiography and microangiopathy. Lancet 1999;353:1586-7.
6. 6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355:517-22.
7. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-81.
8. Olszewski AJ, Szostak WB, Bialkowska M, Rudnicki S, McCully KS. Reduction of plasma lipid and homocysteine levels by pyridoxine, folate, cobalamin, choline, riboflavin, and troxerutin in atherosclerosis. Atherosclerosis 1989;75:1-6.
9. 6 plus folic acid therapy in young patients with arteriosclerosis and hyperhomocysteinemia. J Vasc Surg 1994;20:933-40.
10. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
11. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D et al. A prospective study of plasma homocyst (e) ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877-81.
12. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
13. Peterson JC, Spence JD. Vitamins and progression of atherosclerosis in hyper-homocyst(e)inaemia. Lancet 1998;351:263.
14. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991;337:1235-43.
15. Sierra C, La SA, Mercader J, Gomez-Angelats E, Urbano-Marquez A, Coca A et al. Silent cerebral white matter lesions in middle-aged essential hypertensive patients. J Hypertens 2002;20:519-24.
16. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout HJ et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994;44:1246-52.
17. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
18. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R et al. Homocysteine, silent brain infarcts, and white matter lesions. The Rotterdam Scan Study. Ann Neurol 2002;51:285-9.
19. Hogervorst E, Ribeiro HM, Molyneux A, Budge M, Smith AD. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol 2002;59:787-93.
20. Hoogeveen EK, Kostense PJ, Eysink PE, Polak BC, Beks PJ, Jakobs C et al. Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: the Hoorn study. Arch Intern Med 2000;160:2984-90.
21. Vaccaro O, Ingrosso D, Rivellese A, Greco G, Riccardi G. Moderate hyperhomocysteinaemia and retinopathy in insulin-dependent diabetes. Lancet 1997;349:1102-3.
22. Hoogeveen EK, Kostense PJ, Jager A, Heine RJ, Jakobs C, Bouter LM et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998;54:203-9.
23. Jager A, Kostense PJ, Nijpels G, Dekker JM, Heine RJ, Bouter LM et al. Serum homocysteine levels are associated with the development of (micro) albuminuria: the Hoorn study. Arterioscler Thromb Vasc Biol 2001;21:74-81.
24. Anderson CM, Saloner D, Lee RE, Griswold VJ, Shapeero LG, Rapp JH et al. Assessment of carotid artery stenosis by MR angiography: comparison with X-ray angiography and color-coded Doppler ultrasound. Am J Neuroradiol 1992;13:989-1003.
25. Litt AW, Eidelman EM, Pinto RS, Riles TS, McLachlan SJ, Schwartzenberg S et al. Diagnosis of carotid artery stenosis: comparison of 2DFT time-of-flight MR angiography with contrast angiography in 50 patients. AJNR Am J Neuroradiol 1991;12:149-54.
26. Ghika J, Bogousslavsky J. Pathophysiology, diagnosis and management. In: Ginsberg M, Bogousslavsky J, editors. Subcortical Arteriosclerotic Encephalopathy (Binswanger's Disease). MA: Blackwell Malden; 1998. pp.1755-71.
27. Ludolph AC, Ullrich K, Bick U, Fahrendorf G, Przyrembel H. Functional and morphological deficits in late-treated patients with homocystinuria: a clinical, electrophysiologic and MRI study. Acta Neurol Scand 1991;83:161-5.
28. Mirowitz SA, Sartor K, Prensky AJ, Gado M, Hodges FJ III Neurodegenerative diseases of childhood: MR and CT evaluation. J Comput Assist Tomogr 1991;15:210-22.
29. van den Berg M, van der Knaap MS, Boers GH, Stehouwer CDA, Rauwerda JA, Valk J et al. Hyperhomocysteinaemia; with reference to its neuroradiological aspects. Neuroradiology 1995;37:403-11.